Unlock stock picks and a broker-level newsfeed that powers Wall Street.
OTC Markets OTCPK - Delayed Quote USD

NovelStem International Corp. (NSTM)

Compare
0.0100
0.0000
(0.00%)
At close: April 4 at 4:00:00 PM EDT
Loading Chart for NSTM
  • Previous Close 0.0000
  • Open 0.0100
  • Bid 0.0081 x --
  • Ask 0.0120 x --
  • Day's Range 0.0100 - 0.0100
  • 52 Week Range 0.0100 - 0.0700
  • Volume 10,000
  • Avg. Volume 3,522
  • Market Cap (intraday) 468,815
  • Beta (5Y Monthly) 0.63
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0700
  • Earnings Date Apr 7, 2025 - Apr 13, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date Apr 2, 2018
  • 1y Target Est --

NovelStem International Corp., a development stage biotechnology holding company, focuses on development and commercialization of stem cell-based diagnostic technology for cancer treatments and to reduce resistance to chemotherapy. The company was formerly known as Hollywood Media Corp. and changed its name to NovelStem International Corp. in September 2018. NovelStem International Corp. was incorporated in 1993 and is headquartered in Boca Raton, Florida.

www.novelstem.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: NSTM

View More

Performance Overview: NSTM

Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

NSTM
0.00%
S&P 500 (^GSPC)
13.73%

1-Year Return

NSTM
83.33%
S&P 500 (^GSPC)
1.42%

3-Year Return

NSTM
96.00%
S&P 500 (^GSPC)
10.72%

5-Year Return

NSTM
90.00%
S&P 500 (^GSPC)
103.89%

Compare To: NSTM

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: NSTM

View More

Valuation Measures

Annual
As of 4/4/2025
  • Market Cap

    421.93k

  • Enterprise Value

    4.68M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    35.16

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    390.34

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -51.40%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    12k

  • Net Income Avi to Common (ttm)

    -3.02M

  • Diluted EPS (ttm)

    -0.0700

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    45.32k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -616.35k

Research Analysis: NSTM

View More

Company Insights: NSTM

Research Reports: NSTM

View More

People Also Watch